Citations (21)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Clara G. Chisari, Simona Toscano, Emanuele D’Amico, Salvatore Lo Fermo, Aurora Zanghì, Sebastiano Arena, Mario Zappia & Francesco Patti. (2019) An update on the safety of treating relapsing-remitting multiple sclerosis. Expert Opinion on Drug Safety 18:10, pages 925-948.
Read now
Read now
Barry Hendin, Robert T Naismith, Sibyl E Wray, Deren Huang, Qunming Dong, Terrie Livingston, Daniel L Jones, Crystal Watson & Mehul Jhaveri. (2018) Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks. Patient Preference and Adherence 12, pages 1289-1297.
Read now
Read now
Articles from other publishers (19)
Taras O. Simaniv, Maria N. Zakharova, Kirill V. Sapozhnikov, Daria G. Tolkacheva, Valeria D. Sokolova, Natalia A. Sableva, Olga N. Mironenko & Taras V. Khimich. (2024) Efficacy and Safety of PEGylated Interferons for Relapsing-Remitting Multiple Sclerosis in Adult Patients: Results of Matching-Adjusted Indirect Comparison. Annals of Clinical and Experimental Neurology 18:1, pages 44-54.
Crossref
Crossref
Mina Mohammadinasr, Soheila Montazersaheb, Hormoz Ayromlou, Vahid Hosseini, Ommoleila Molavi & Mohammad Saeid Hejazi. (2024) Exosome Content–Mediated Signaling Pathways in Multiple Sclerosis. Molecular Neurobiology.
Crossref
Crossref
Robert W. Baumhefner & Mei Leng. (2022) Standard Dose Weekly Intramuscular Beta Interferon-1a May Be Inadequate for Some Patients with Multiple Sclerosis: A 19-Year Clinical Experience Using Twice a Week Dosage. Neurology and Therapy 11:3, pages 1399-1408.
Crossref
Crossref
Stanley L. Cohan, Barry A. Hendin, Anthony T. Reder, Kyle Smoot, Robin Avila, Jason P. Mendoza & Bianca Weinstock-Guttman. (2021) Interferons and Multiple Sclerosis: Lessons from 25 Years of Clinical and Real-World Experience with Intramuscular Interferon Beta-1a (Avonex). CNS Drugs 35:7, pages 743-767.
Crossref
Crossref
Jennifer Vandooren, Rafaela Vaz Sousa Pereira, Estefania Ugarte-Berzal, Vasily Rybakin, Sam Noppen, Melissa R. Stas, Eline Bernaerts, Eva Ganseman, Mieke Metzemaekers, Dominique Schols, Paul Proost & Ghislain Opdenakker. (2021) Internal Disulfide Bonding and Glycosylation of Interleukin-7 Protect Against Proteolytic Inactivation by Neutrophil Metalloproteinases and Serine Proteases. Frontiers in Immunology 12.
Crossref
Crossref
Ghislain Opdenakker & Jo Van Damme. (2021) Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity. Cytokine & Growth Factor Reviews 58, pages 134-140.
Crossref
Crossref
Marcello Moccia, Ilaria Loperto, Roberta Lanzillo, Antonio Capacchione, Antonio Carotenuto, Maria Triassi, Vincenzo Brescia Morra & Raffaele Palladino. (2020) Persistence, adherence, healthcare resource utilisation and costs for interferon Beta in multiple sclerosis: a population-based study in the Campania region (southern Italy). BMC Health Services Research 20:1.
Crossref
Crossref
Ghislain Opdenakker, Ahmed Abu El-Asrar & Jo Van Damme. (2020) Remnant Epitopes Generating Autoimmunity: From Model to Useful Paradigm. Trends in Immunology 41:5, pages 367-378.
Crossref
Crossref
John Axford, Azita Alavi, Rick Cummings, Gordan Lauc, Ghislain Opdenakker, Celso Reis & Pauline Rudd. (2019) Translational glycobiology: from bench to bedside. Journal of the Royal Society of Medicine 112:10, pages 424-427.
Crossref
Crossref
Suzi B. Claflin, Simon Broadley & Bruce V. Taylor. (2019) The Effect of Disease Modifying Therapies on Disability Progression in Multiple Sclerosis: A Systematic Overview of Meta-Analyses. Frontiers in Neurology 9.
Crossref
Crossref
Robert T Naismith, Barry Hendin, Sibyl Wray, DeRen Huang, Fiorenza Gaudenzi, Qunming Dong, Bjørn Sperling, Monica Mann & Brian Werneburg. (2019) Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results. Multiple Sclerosis Journal - Experimental, Translational and Clinical 5:1, pages 205521731882214.
Crossref
Crossref
Noelia Villarrubia, Eulalia Rodríguez-Martín, Elisenda Alari-Pahissa, Larraitz Aragón, Tamara Castillo-Triviño, Herena Eixarch, Joana María Ferrer, José Enrique Martínez-Rodríguez, Margarita Massot, María Jesús Pinto-Medel, Álvaro Prada, Breogán Rodríguez-Acevedo, Patricia Urbaneja, Francisco Gascón-Gimenez, Guadalupe Herrera, Rocío Hernández-Clares, María Gema Salgado, Agustín Oterino, David San Segundo, Juan Pablo Cuello, Juana Gil-Herrera, Carmen Cámara, Montserrat Gómez-Gutiérrez, Eugenia Martínez-Hernández, Virginia Meca-Lallana, Esther Moga, Cecilia Muñoz-Calleja, Luis Querol, Silvia Presas-Rodríguez, Aina Teniente-Serra, Alexandru Vlagea, Alfonso Muriel, Ernesto Roldán & Luisa María Villar. (2019) Multi-centre validation of a flow cytometry method to identify optimal responders to interferon-beta in multiple sclerosis. Clinica Chimica Acta 488, pages 135-142.
Crossref
Crossref
Dejan Jakimovski, Channa Kolb, Murali Ramanathan, Robert Zivadinov & Bianca Weinstock-Guttman. (2018) Interferon β for Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine 8:11, pages a032003.
Crossref
Crossref
Ida Manna, Enrico Iaccino, Vincenzo Dattilo, Stefania Barone, Eleonora Vecchio, Selena Mimmi, Enrica Filippelli, Giulio Demonte, Serena Polidoro, Alfredo Granata, Sara Scannapieco, Ileana Quinto, Paola Valentino & Aldo Quattrone. (2018) Exosome‐associated miRNA profile as a prognostic tool for therapy response monitoring in multiple sclerosis patients. The FASEB Journal 32:8, pages 4241-4246.
Crossref
Crossref
D. Biotti & J. Ciron. (2018) First-line therapy in relapsing remitting multiple sclerosis. Revue Neurologique 174:6, pages 419-428.
Crossref
Crossref
Marcello Moccia, Raffaele Palladino, Antonio Carotenuto, Francesco Saccà, Cinzia Valeria Russo, Roberta Lanzillo & Vincenzo Brescia Morra. (2018) A 8-year retrospective cohort study comparing Interferon-β formulations for relapsing‐remitting multiple sclerosis. Multiple Sclerosis and Related Disorders 19, pages 50-54.
Crossref
Crossref
Raquel Alenda, Lucienne Costa-Frossard, Roberto Alvarez-Lafuente, Carmen Espejo, Eulalia Rodríguez-Martín, Susana Sainz de la Maza, Noelia Villarrubia, Jordi Río, María I. Domínguez-Mozo, Xavier Montalban, José C. Álvarez-Cermeño & Luisa M. Villar. (2017) Blood lymphocyte subsets identify optimal responders to IFN-beta in MS. Journal of Neurology 265:1, pages 24-31.
Crossref
Crossref
. (2017) Chinese Guidelines for the Diagnosis and Management of Tumefactive Demyelinating Lesions of Central Nervous System. Chinese Medical Journal 130:15, pages 1838-1850.
Crossref
Crossref
Vincenzo Dattola, Lilla Bonanno, Antonino Naro, Antonino Chillura, Anna Lisa Logiudice, Edoardo Sessa, Fausto Famà, Angelo Quartarone, Rocco Salvatore Calabrò, Silvia Marino & Margherita Russo. (2017) Relationship between Interferon Beta-1A Administration and Intracranial Vascular Tone Regulation in Patients with Relapsing-Remitting Multiple Sclerosis: A Pilot Study. BioMed Research International 2017, pages 1-5.
Crossref
Crossref